Drug Trial Radar · NCT06028074
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
111
Planned (sponsor's estimate)
Start
Dec 12, 2023
Primary completion
Sep 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Georgiamune IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Conditions
- Advanced Solid Malignancies
Interventions
GIM122Drug
GIM-122 administered IV once every 3 weeks or every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities [DLT] with GIM-122Time frame: 18 months
- Maximum tolerated dose [MTD] of GIM-122Time frame: 18 months
- Recommended Phase 2 Dose [RP2D] of GIM-122Time frame: 18 Months
- Overall response rate (ORR) -Part B of the studyTime frame: 36 months
- Anti-tumor activity of GIM-122Time frame: 36 months
- Incidence and severity of AE / SAEs and tolerabilityTime frame: 36 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
The Angeles Clinic and Research Institute
Los Angeles, California · Recruiting
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCLA Hematology/Oncology
Los Angeles, California · Recruiting
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
Rutgers Cancer Institute of NJ
New Brunswick, New Jersey · Recruiting
Tennessee Oncology, PLLC
Nashville, Tennessee · Recruiting
Texas Oncology - Baylor Sammons Cancer Center
Dallas, Texas · Recruiting
NEXT Oncology Dallas
Irving, Texas · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.